...
首页> 外文期刊>Investigative ophthalmology & visual science >Characterization of a Novel Intraocular Drug-Delivery System Using Crystalline Lipid Antiviral Prodrugs of Ganciclovir and Cyclic Cidofovir.
【24h】

Characterization of a Novel Intraocular Drug-Delivery System Using Crystalline Lipid Antiviral Prodrugs of Ganciclovir and Cyclic Cidofovir.

机译:更昔洛韦和环西多福韦结晶脂质抗病毒前药的新型眼内药物传递系统的表征。

获取原文
获取原文并翻译 | 示例
           

摘要

PURPOSE: In an earlier study, a novel intraocular drug-delivery system was reported in which hexadecyloxypropyl-phospho-ganciclovir (HDP-P-GCV) was used as a prototype. The hypothesis was that many biologically effective compounds could be modified to crystalline lipid prodrugs and could be delivered directly into the vitreous in a long-lasting, slow-release form. This study was undertaken to characterize this new drug-delivery system further, by using small particles of HDP-P-GCV and hexadecyloxypropyl-cyclic cidofovir (HDP-cCDV). METHODS: HDP-P-GCV was microfluidized into 4.4-渭m (median) particles, injected into rabbit vitreous. The vitreous drug level was then measured at different time points. Crystalline HDP-cCDV was synthesized, suspended in 5% dextrose, and injected into the rabbit's vitreous at 10, 55, 100, 550, or 1000 渭g in 50 渭L vehicle per eye, to determine the highest nontoxic dose. The dose, 100 渭g, was injected into 24 rabbit eyes, to evaluate pharmacokinetics; into 14 rabbit eyes with established HSV retinitis, to evaluate its efficacy; and into 58 rabbit eyes before herpes simplex virus (HSV) infection to evaluate its intraocular antiviral duration. RESULTS: Microfluidized particles of HDP-P-GCV showed an increased drug release rate compared with the large-particle drug formulation, with area under concentration-time curve (AUC) of 219.8 +/- 114.1 (n = 3) versus 108.3 +/- 47.2 (n = 3) for unmodified HDP-P-GCV during the 12-week period after a 2.8-micromole intravitreal injection. There was a 103% increase of the drug released from the microfluidized formulation of HDP-P-GCV versus the unmodified formulation. Intravitreal injections of HDP-cCDV at doses of 100 渭g/eye or lower were not toxic. After the 100 渭g/eye injections, HPLC analysis showed a vitreous HDP-cCDV level of 0.05 渭M at week 5, which declined to 0.002 渭M at week 8. The concentration at week 8 (0.002 渭M) remained above the IC(50) for cytomegalovirus (0.0003 渭M). The pretreatment study demonstrated an antiviral effect that lasted 100 days after a single intravitreal injection. CONCLUSIONS: This crystalline lipid prodrug intravitreal delivery system is an effective approach to achieving sustained, therapeutic drug levels in the eye. Small microfluidized particles of HDP-P-GCV provide more rapid dissolution and higher vitreous drug levels.
机译:目的:在较早的研究中,报道了一种新颖的眼内药物递送系统,其中十六烷氧基丙基-磷酸-更昔洛韦(HDP-P-GCV)被用作原型。假设是许多生物学上有效的化合物都可以被修饰成结晶脂质前药,并且可以以持久,缓慢释放的形式直接递送到玻璃体中。通过使用小颗粒的HDP-P-GCV和十六烷氧基丙基环西多福韦(HDP-cCDV),进行了这项研究以进一步表征这种新的药物递送系统。方法:将HDP-P-GCV微流化为4.4-μm(中值)颗粒,注入兔玻璃体中。然后在不同时间点测量玻璃体药物水平。合成结晶HDP-cCDV,将其悬浮在5%葡萄糖中,然后以每只眼50μL的载体以10、55、100、550或1000μg的剂量注射到兔子的玻璃体中,以确定最高的无毒剂量。将100μg的剂量注射入24只兔眼,以评估药代动力学。进入14只患有HSV视网膜炎的兔子眼睛,以评估其疗效;并在58只兔眼中感染单纯疱疹病毒(HSV),以评估其眼内抗病毒持续时间。结果:与大颗粒药物制剂相比,HDP-P-GCV微流化颗粒显示出更高的药物释放速率,浓淡-时间曲线下的面积(AUC)为219.8 +/- 114.1(n = 3)对108.3 + / -在2.8微摩尔玻璃体内注射后的12周内,未修饰的HDP-P-GCV为47.2(n = 3)。与未经修饰的制剂相比,从HDP-P-GCV微流化制剂释放的药物增加了103%。以100μg/眼或更低的剂量玻璃体内注射HDP-cCDV无毒。注射100μg/眼后,HPLC分析显示,第5周时玻璃体HDP-cCDV水平为0.05μM,第8周时下降至0.002μM。第8周时的浓度(0.002μM)仍高于IC (50)用于巨细胞病毒(0.0003μM)。预处理研究表明,单次玻璃体内注射后抗病毒作用持续100天。结论:该结晶脂质前药玻璃体内递送系统是实现眼中持续的治疗药物水平的有效方法。 HDP-P-GCV的微流化小颗粒可提供更快的溶出度和更高的玻璃态药物水平。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号